SCHEDULE: CVI Investments & Heights Capital Report 6.3% Stake in Aptevo Therapeutics

CVI Investments, Inc. and Heights Capital Management, Inc. have jointly filed a Schedule 13G, reporting beneficial ownership of 6.3% of Aptevo Therapeutics Inc. common stock, primarily through exercisable warrants.

Summary

• CVI Investments, Inc. and Heights Capital Management, Inc. are reporting their beneficial ownership of Aptevo Therapeutics Inc. common stock.
• The total beneficial ownership is 83,854 shares, representing 6.3% of the class of securities.
• This ownership is primarily derived from the exercise of warrants, with a cap of 9.99% on exercisability to avoid exceeding beneficial ownership thresholds.
• Heights Capital Management, Inc. acts as the investment manager for CVI Investments, Inc. and may exercise voting and dispositive power over these shares.
• The filing is an amendment (Amendment No. 3) to a previous Schedule 13G filing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting on beneficial ownership changes rather than operational or financial performance.

Positives

• The filing clearly discloses the beneficial ownership stake, providing transparency to the market.
• The reporting entities are established investment managers, suggesting a strategic investment approach.

Negatives

• The filing does not contain any operational or financial performance data for Aptevo Therapeutics Inc.
• The ownership is contingent on warrant exercise and subject to a 9.99% beneficial ownership limit, indicating potential limitations on direct control or influence.

Risks

• The ownership is primarily through warrants, which are subject to exercise and potential dilution if the company issues more shares.
• The 9.99% ownership cap limits the reporting persons' ability to gain controlling interest through these specific holdings.
• Future changes in warrant exercise or market conditions could alter the reported beneficial ownership percentage.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Aptevo Therapeutics Inc.'s future performance. It solely reports on current beneficial ownership.

Management Comments

• Heights Capital Management, Inc. serves as the investment manager to CVI Investments, Inc. and as such may exercise voting and dispositive power over the shares reported as beneficially owned by CVI Investments, Inc. herein.
• Each of the Reporting Persons hereby disclaims any beneficial ownership of any such Shares, except for their pecuniary interest therein.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in public companies. This filing indicates a notable, though not controlling, position in Aptevo Therapeutics by CVI Investments and Heights Capital Management, likely as part of their broader investment strategies.

Stakeholder Impact

• Shareholders of Aptevo Therapeutics Inc. are informed of a significant beneficial owner, potentially influencing market perception.
• The disclosure provides clarity on the investment positions of CVI Investments and Heights Capital Management, impacting their investor relations.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership levels in Aptevo Therapeutics Inc.
• Further amendments to this Schedule 13G will be filed if changes in beneficial ownership meet reporting thresholds.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, CVI Investments, Heights Capital Management, Aptevo Therapeutics, Warrants, Investment Management, SEC Filing